140 related articles for article (PubMed ID: 8856115)
1. A new generation of bradykinin antagonists.
Stewart JM; Gera L; Hanson W; Zuzack JS; Burkard M; McCullough R; Whalley ET
Immunopharmacology; 1996 Jun; 33(1-3):51-60. PubMed ID: 8856115
[TBL] [Abstract][Full Text] [Related]
2. Potent, long-acting bradykinin antagonists for a wide range of applications.
Stewart JM; Gera L; Chan DC; Whalley ET; Hanson WL; Zuzack JS
Can J Physiol Pharmacol; 1997 Jun; 75(6):719-24. PubMed ID: 9276154
[TBL] [Abstract][Full Text] [Related]
3. A new class of bradykinin antagonists containing indanylglycine.
Gera L; Stewart JM
Immunopharmacology; 1996 Jun; 33(1-3):174-7. PubMed ID: 8856143
[No Abstract] [Full Text] [Related]
4. In vivo pharmacological profile of novel, potent, stable BK antagonists at B1 and B2 receptors.
Hanson WL; McCullough RG; Selig WM; Wieczorek M; Ross S; Whalley ET; Stewart JM; Gera L
Immunopharmacology; 1996 Jun; 33(1-3):191-3. PubMed ID: 8856147
[No Abstract] [Full Text] [Related]
5. Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
Goodfellow VS; Marathe MV; Kuhlman KG; Fitzpatrick TD; Cuadrado D; Hanson W; Zuzack JS; Ross SE; Wieczorek M; Burkard M; Whalley ET
J Med Chem; 1996 Mar; 39(7):1472-84. PubMed ID: 8691478
[TBL] [Abstract][Full Text] [Related]
6. Peptide and non-peptide bradykinin B2 receptor agonists and antagonists: a reappraisal of their pharmacology in the guinea-pig ileum.
Meini S; Patacchini R; Lecci A; Quartara L; Maggi CA
Eur J Pharmacol; 2000 Dec; 409(2):185-94. PubMed ID: 11104833
[TBL] [Abstract][Full Text] [Related]
7. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.
Stewart JM; Gera L; Chan DC; York EJ; Simkeviciene V; Bunn PA; Taraseviciene-Stewart L
Peptides; 2005 Aug; 26(8):1288-91. PubMed ID: 15878795
[TBL] [Abstract][Full Text] [Related]
8. Comparative profile of novel potent bradykinin antagonists at human B1 and B2 receptors.
Burkard M; Zuzack JS; Jones S; Francis M; Whalley ET; Stewart JM; Gera L
Immunopharmacology; 1996 Jun; 33(1-3):186-90. PubMed ID: 8856146
[TBL] [Abstract][Full Text] [Related]
9. Correlation of secondary structures of bradykinin B1 receptor antagonists with their activity.
Miskolzie M; Gera L; Stewart JM; Kotovych G
J Biomol Struct Dyn; 2002 Feb; 19(4):585-93. PubMed ID: 11843620
[TBL] [Abstract][Full Text] [Related]
10. Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat.
Uknis AB; DeLa Cadena RA; Janardham R; Sartor RB; Whalley ET; Colman RW
Inflamm Res; 2001 Mar; 50(3):149-55. PubMed ID: 11339503
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of multifunctional ligands targeting opioid and bradykinin 2 receptors.
Deekonda S; Rankin D; Davis P; Lai J; Porreca F; Hruby VJ
Bioorg Med Chem Lett; 2015 Oct; 25(19):4148-52. PubMed ID: 26316468
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo effects of the new nonpeptide bradykinin B2 receptor antagonist, LF 16-0335C, on guinea-pig and rat kinin receptors.
Pruneau D; Luccarini JM; Fouchet C; Defrêne E; Franck RM; Loillier B; Duclos H; Robert C; Cremers B; Bélichard P; Paquet JL
Fundam Clin Pharmacol; 1999; 13(1):75-83. PubMed ID: 10027091
[TBL] [Abstract][Full Text] [Related]
13. Potent, long-acting, orally-active bradykinin antagonists for a wide range of applications.
Stewart JM; Gera L; Chan DC; Whalley ET; Hanson WL; Zuzack JS
Immunopharmacology; 1997 Jun; 36(2-3):167-72. PubMed ID: 9228542
[TBL] [Abstract][Full Text] [Related]
14. Characterization of bradykinin B(2) receptor antagonists in human and rat urinary bladder.
Meini S; Patacchini R; Giuliani S; Lazzeri M; Turini D; Maggi CA; Lecci A
Eur J Pharmacol; 2000 Jan; 388(2):177-82. PubMed ID: 10666510
[TBL] [Abstract][Full Text] [Related]
15. Inflammation modifies the role of cyclooxygenases in the contractile responses of the rat detrusor smooth muscle to kinin agonists.
Meini S; Lecci A; Cucchi P; Catalioto RM; Criscuoli M; Maggi CA
J Pharmacol Exp Ther; 1998 Oct; 287(1):137-43. PubMed ID: 9765332
[TBL] [Abstract][Full Text] [Related]
16. A new class of potent bradykinin antagonist dimers.
Gera L; Stewart JM; Whalley E; Burkard M; Zuzack JS
Immunopharmacology; 1996 Jun; 33(1-3):178-82. PubMed ID: 8856144
[No Abstract] [Full Text] [Related]
17. Bradykinin-related compounds as new drugs for cancer and inflammation.
Stewart JM; Gera L; Chan DC; Bunn PA; York EJ; Simkeviciene V; Helfrich B
Can J Physiol Pharmacol; 2002 Apr; 80(4):275-80. PubMed ID: 12025961
[TBL] [Abstract][Full Text] [Related]
18. A new class of pseudopeptide antagonists of the kinin B1 receptor containing alkyl spacers.
Galoppini C; Meini S; Tancredi M; Di Fenza A; Triolo A; Quartara L; Maggi CA; Formaggio F; Toniolo C; Mazzucco S; Papini A; Rovero P
J Med Chem; 1999 Feb; 42(3):409-14. PubMed ID: 9986712
[TBL] [Abstract][Full Text] [Related]
19. Hybrid peptides having mixed substance P (NK1), neurokinin A (NK2) and bradykinin (BK2) antagonist properties.
Srivastava VP; Goodfellow VS; Zuzack JS; Jones S; Francis M; Beckey VE; Whalley ET
Immunopharmacology; 1996 Jun; 33(1-3):194-7. PubMed ID: 8856148
[No Abstract] [Full Text] [Related]
20. Non-selectivity of new bradykinin antagonists for B1 receptors.
Rhaleb NE; Gobeil F; Regoli D
Life Sci; 1992; 51(11):PL125-9. PubMed ID: 1326066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
